Stock XTNT XTANT MEDICAL HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Xtant Medical Holdings, Inc.

Equities

XTNT

US98420P3082

Market Closed - Nyse
Other stock markets
 04:10:00 2024-05-01 pm EDT 		5-day change 1st Jan Change
0.861 USD -3.76% Intraday chart for Xtant Medical Holdings, Inc. -3.26% -23.81%
Apr. 30 Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds CI
Apr. 01 Xtant Medical Files $150 Million Mixed Shelf; Shares Fall MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 71% by 2026.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
XTANT MEDICAL HOLDINGS, INC. Stock Xtant Medical Holdings, Inc.
-23.81% 112M -
SMITH & NEPHEW PLC Stock Smith & Nephew Plc
-9.45% 10.63B
A-
IMEIK TECHNOLOGY DEVELOPMENT CO.,LTD. Stock Imeik Technology Development Co.,Ltd.
+2.17% 8.92B
C
INSPIRE MEDICAL SYSTEMS, INC. Stock Inspire Medical Systems, Inc.
+19.94% 7.39B
C
GLAUKOS CORPORATION Stock Glaukos Corporation
+24.43% 4.96B
B+
AXONICS, INC. Stock Axonics, Inc.
+7.46% 3.41B
C-
ENOVIS CORPORATION Stock Enovis Corporation
-1.11% 3.04B
B-
BEIJING BALANCE MEDICAL TECHNOLOGY CO.,LTD. Stock Beijing Balance Medical Technology Co.,Ltd.
-5.07% 2.23B - -
SHANGHAI MICROPORT ENDOVASCULAR MEDTECH CO., LTD. Stock Shanghai MicroPort Endovascular MedTech Co., Ltd.
-4.22% 2.13B -
DOUBLE MEDICAL TECHNOLOGY INC. Stock Double Medical Technology Inc.
-20.87% 1.84B -
C-
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XTNT Stock
  4. Ratings Xtant Medical Holdings, Inc.